Searched for
SPRYCEL TABLETS
Lupin rolls out generic oncology drug in US marketDrug firm Lupin has launched a generic cancer treatment medication in the US. The company introduced Dasatinib Tablets in various strengths...- Alembic Pharmaceuticals gets USFDA nod for generic blood cancer treatment drugAlembic Pharmaceuticals has secured final approval from the USFDA for its generic Dasatinib tablets. These tablets are used to treat certai...
- Aurobindo Pharma arm gets USFDA nod for generic blood cancer drugAurobindo Pharma's subsidiary, Eugia Pharma Specialities Ltd, has secured USFDA approval to produce and sell generic Dasatinib tablets, use...
- Zydus Lifesciences shares zoom 7% after USFDA nod for Dasatinib tabletsZydus Lifesciences share price: Zydus Lifesciences shares rose 7% following USFDA's final approval to market Dasatinib tablets across multi...
- Stocks in the news: Voda Idea, NDTV, Lupin, LTTS, Macrotech, and KIMSAdani group and NDTV's promoter entity RRPR Holding have approached Sebi, seeking clarity on the applicability of the regulator's earlier o...
- Lupin gets USFDA nod for generic cancer treatment drugLupin in partnership with Pharmascience Inc. has received approval from the US Food and Drug Administration (FDA) for Dasatinib tablets in ...
- Alembic gets USFDA nod for cancer treatment drugDasatinib Tablet is indicated for the treatment of newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) i...
- Cheaper version of cancer drug Dasatinib will have to waitDIPP has shot down a health ministry proposal to consider a government-initiated compulsory licence for cancer drug Dasatinib.
- BDR seeks CL for cancer drug, offers 95% cheaper generic copyThe Mumbai-based firm has applied to the Controller of Patents, Mumbai, seeking the CL for "ease of availability" and "affordability" of th...
- BDR Pharma seeks cancer drug licenceBDR Pharma has filed an application with the Mumbai Patent Office, seeking compulsory licence to market a crucial cancer drug, dasatinib
Load More
